These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38195117)

  • 1. CLN3 deficiency leads to neurological and metabolic perturbations during early development.
    Heins-Marroquin U; Singh RR; Perathoner S; Gavotto F; Merino Ruiz C; Patraskaki M; Gomez-Giro G; Kleine Borgmann F; Meyer M; Carpentier A; Warmoes MO; Jäger C; Mittelbronn M; Schwamborn JC; Cordero-Maldonado ML; Crawford AD; Schymanski EL; Linster CL
    Life Sci Alliance; 2024 Mar; 7(3):. PubMed ID: 38195117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synapse alterations precede neuronal damage and storage pathology in a human cerebral organoid model of CLN3-juvenile neuronal ceroid lipofuscinosis.
    Gomez-Giro G; Arias-Fuenzalida J; Jarazo J; Zeuschner D; Ali M; Possemis N; Bolognin S; Halder R; Jäger C; Kuper WFE; van Hasselt PM; Zaehres H; Del Sol A; van der Putten H; Schöler HR; Schwamborn JC
    Acta Neuropathol Commun; 2019 Dec; 7(1):222. PubMed ID: 31888773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CLN3 is required for the clearance of glycerophosphodiesters from lysosomes.
    Laqtom NN; Dong W; Medoh UN; Cangelosi AL; Dharamdasani V; Chan SH; Kunchok T; Lewis CA; Heinze I; Tang R; Grimm C; Dang Do AN; Porter FD; Ori A; Sabatini DM; Abu-Remaileh M
    Nature; 2022 Sep; 609(7929):1005-1011. PubMed ID: 36131016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycerophosphodiesters inhibit lysosomal phospholipid catabolism in Batten disease.
    Nyame K; Hims A; Aburous A; Laqtom NN; Dong W; Medoh UN; Heiby JC; Xiong J; Ori A; Abu-Remaileh M
    Mol Cell; 2024 Apr; 84(7):1354-1364.e9. PubMed ID: 38447580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cln3-mutations underlying juvenile neuronal ceroid lipofuscinosis cause significantly reduced levels of Palmitoyl-protein thioesterases-1 (Ppt1)-protein and Ppt1-enzyme activity in the lysosome.
    Appu AP; Bagh MB; Sadhukhan T; Mondal A; Casey S; Mukherjee AB
    J Inherit Metab Dis; 2019 Sep; 42(5):944-954. PubMed ID: 31025705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel c.1135_1138delCTGT mutation in CLN3 leads to juvenile neuronal ceroid lipofuscinosis.
    Drack AV; Miller JN; Pearce DA
    J Child Neurol; 2013 Sep; 28(9):1112-6. PubMed ID: 23877479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene correction of the CLN3 c.175G>A variant in patient-derived induced pluripotent stem cells prevents pathological changes in retinal organoids.
    Zhang X; Zhang D; Thompson JA; Chen SC; Huang Z; Jennings L; McLaren TL; Lamey TM; De Roach JN; Chen FK; McLenachan S
    Mol Genet Genomic Med; 2021 Mar; 9(3):e1601. PubMed ID: 33497524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of CLN3, the gene mutated in juvenile neuronal ceroid lipofuscinosis, leads to metabolic impairment and autophagy induction in retinal pigment epithelium.
    Zhong Y; Mohan K; Liu J; Al-Attar A; Lin P; Flight RM; Sun Q; Warmoes MO; Deshpande RR; Liu H; Jung KS; Mitov MI; Lin N; Butterfield DA; Lu S; Liu J; Moseley HNB; Fan TWM; Kleinman ME; Wang QJ
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165883. PubMed ID: 32592935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRPML1 activation ameliorates lysosomal phenotypes in CLN3 deficient retinal pigment epithelial cells.
    Wünkhaus D; Tang R; Nyame K; Laqtom NN; Schweizer M; Scotto Rosato A; Krogsæter EK; Wollnik C; Abu-Remaileh M; Grimm C; Hermey G; Kuhn R; Gruber-Schoffnegger D; Markmann S
    Sci Rep; 2024 Jul; 14(1):17469. PubMed ID: 39080379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel in-frame mutation in
    Sher M; Farooq M; Abdullah U; Ali Z; Faryal S; Zakaria M; Ullah F; Bukhari H; Møller RS; Tommerup N; Baig SM
    Int J Neurosci; 2019 Sep; 129(9):890-895. PubMed ID: 30892110
    [No Abstract]   [Full Text] [Related]  

  • 11. Profound infantile neuroretinal dysfunction in a heterozygote for the CLN3 genetic defect.
    de los Reyes E; Dyken PR; Phillips P; Brodsky M; Bates S; Glasier C; Mrak RE
    J Child Neurol; 2004 Jan; 19(1):42-6. PubMed ID: 15032383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating membrane fluidity corrects Batten disease phenotypes in vitro and in vivo.
    Schultz ML; Tecedor L; Lysenko E; Ramachandran S; Stein CS; Davidson BL
    Neurobiol Dis; 2018 Jul; 115():182-193. PubMed ID: 29660499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen presenting cell abnormalities in the Cln3(-/-) mouse model of juvenile neuronal ceroid lipofuscinosis.
    Hersrud SL; Kovács AD; Pearce DA
    Biochim Biophys Acta; 2016 Jul; 1862(7):1324-36. PubMed ID: 27101989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deterioration of visual quality and acuity as the first sign of ceroid lipofuscinosis type 3 (CLN3), a rare neurometabolic disease.
    Purzycka-Olewiecka JK; Hetmańczyk-Sawicka K; Kmieć T; Szczęśniak D; Trubicka J; Krawczyński M; Pronicki M; Ługowska A
    Metab Brain Dis; 2023 Feb; 38(2):709-715. PubMed ID: 36576693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3).
    Bosch ME; Aldrich A; Fallet R; Odvody J; Burkovetskaya M; Schuberth K; Fitzgerald JA; Foust KD; Kielian T
    J Neurosci; 2016 Sep; 36(37):9669-82. PubMed ID: 27629717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered flurothyl seizure induction latency, phenotype, and subsequent mortality in a mouse model of juvenile neuronal ceroid lipofuscinosis/batten disease.
    Kriscenski-Perry E; Applegate CD; Serour A; Mhyre TR; Leonardo CC; Pearce DA
    Epilepsia; 2002 Oct; 43(10):1137-40. PubMed ID: 12366726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene.
    Sondhi D; Scott EC; Chen A; Hackett NR; Wong AM; Kubiak A; Nelvagal HR; Pearse Y; Cotman SL; Cooper JD; Crystal RG
    Hum Gene Ther; 2014 Mar; 25(3):223-39. PubMed ID: 24372003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel role of the Batten disease gene CLN3: association with BMP synthesis.
    Hobert JA; Dawson G
    Biochem Biophys Res Commun; 2007 Jun; 358(1):111-6. PubMed ID: 17482562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcript and in silico analysis of CLN3 in juvenile neuronal ceroid lipofuscinosis and associated mouse models.
    Chan CH; Mitchison HM; Pearce DA
    Hum Mol Genet; 2008 Nov; 17(21):3332-9. PubMed ID: 18678598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using Patient-Specific Induced Pluripotent Stem Cells and Wild-Type Mice to Develop a Gene Augmentation-Based Strategy to Treat CLN3-Associated Retinal Degeneration.
    Wiley LA; Burnight ER; Drack AV; Banach BB; Ochoa D; Cranston CM; Madumba RA; East JS; Mullins RF; Stone EM; Tucker BA
    Hum Gene Ther; 2016 Oct; 27(10):835-846. PubMed ID: 27400765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.